Read More Pharma Industry News Could monthly treatment replace burdensome peanut allergy dosing? Aravax may soon have an answer Aravax gains FDA Fast Track status for PVX108 as Phase 2 peanut allergy data approach and preparations for a possible Phase 3 program advance. bySoujanya RaviAugust 5, 2026